Market Cap 26.62M
Revenue (ttm) 0.00
Net Income (ttm) -96.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,300
Avg Vol 1,298,442
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 25%
Beta 2.79
Analysts Hold
Price Target $4.00

Company Profile

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 620 8501
Address:
18706 North Creek Parkway, Suite 104, Bothell, United States
Latest News on ATHA
No data available.